Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X:
“Renal cancer highlights ESMO26
- Final OS data for LS11 (Lenvatinib/belzutifan vs cabo in pretreated disease) & final OS for KN564 (adjuvant pembro vs placebo) by Toni Choueiri
- 1st line triplet data for Len/pembo/bel vs Len/pembro/CTLA4 vs Len/pembro by Brian Rini Press release shows it’s negative. Triplets appear hard in RCC.
- New monotherapy data for Ivanesimab (VEGF/PD1) and more data. Combination trials to follow
- A randomised phase II of metastasis-directed therapy +/- pembro by Roberto Iacovelli
Finally phase 2 data of ENPP3/CD3 T cell engager.”
You can also read:
10 Must-Read Posts In GU Oncology This Week
